REGENXBIO Total Assets 2014-2022 | RGNX

REGENXBIO total assets from 2014 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.
REGENXBIO Annual Total Assets
(Millions of US $)
2021 $1,114
2020 $708
2019 $498
2018 $544
2017 $199
2016 $173
2015 $221
2014 $3
2013 $3
REGENXBIO Quarterly Total Assets
(Millions of US $)
2022-03-31 $1,025
2021-12-31 $1,114
2021-09-30 $800
2021-06-30 $836
2021-03-31 $879
2020-12-31 $708
2020-09-30 $541
2020-06-30 $450
2020-03-31 $464
2019-12-31 $498
2019-09-30 $509
2019-06-30 $529
2019-03-31 $519
2018-12-31 $544
2018-09-30 $515
2018-06-30 $336
2018-03-31 $317
2017-12-31 $199
2017-09-30 $209
2017-06-30 $224
2017-03-31 $224
2016-12-31 $173
2016-09-30 $196
2016-06-30 $206
2016-03-31 $215
2015-12-31 $221
2015-09-30 $227
2015-06-30 $0
2015-03-31 $0
2014-12-31 $0
2014-09-30 $0
2013-12-31 $3
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.899B $0.470B
REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $161.383B 9.82
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.475B 16.53
Biohaven Pharmaceutical Holding (BHVN) United States $9.944B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.681B 0.00
Emergent Biosolutions (EBS) United States $1.444B 6.18
Arcus Biosciences (RCUS) United States $1.389B 35.22
Myovant Sciences (MYOV) United Kingdom $0.879B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.509B 0.00
Gelesis Holdings (GLS) United States $0.362B 0.00
Zymeworks (ZYME) Canada $0.321B 0.00
Ambrx Biopharma (AMAM) United States $0.159B 0.00
Enzo Biochem (ENZ) United States $0.114B 23.50
SQZ Biotechnologies (SQZ) United States $0.093B 0.00